Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.

@article{Tetef2001PhaseIT,
  title={Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies.},
  author={Merry L. Tetef and Timothy W. Synold and Warren Allen Chow and Lucille A. Leong and Kim A Margolin and Robert Wes Morgan and James W. Raschko and Shigeki Shibata and George Somlo and Yi-Ting Yen and Susan Groshen and Karen Johnson and Heinz-Josef Lenz and David R. Gandara and James H. Doroshow},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 6},
  pages={1569-76}
}
Dexrazoxane is a bidentate chelator of divalent cations. Pretreatment with short infusions of dexrazoxane prior to bolus doxorubicin has been shown to lessen the incidence and severity of anthracycline-associated cardiac toxicity. However, because of rapid, diffusion-mediated cellular uptake and the short plasma half-life of dexrazoxane, combined with prolonged cellular retention of doxorubicin, dexrazoxane may be more effective when administered as a continuous infusion. Thus, a Phase I… CONTINUE READING